Kopp Family Office LLC Sells 8,554 Shares of Vericel Corporation $VCEL

Key Points

• Kopp Family Office LLC has reduced its stake in Vericel Corporation by 4.7% in the second quarter, now holding 172,657 shares after selling 8,554 shares.
• Vericel's latest earnings report showed a revenue of $63.24 million, with an EPS of ($0.01), surpassing the consensus estimate by $0.03.
• Six equities analysts have provided ratings for Vericel, with an average rating of "Moderate Buy" and a price target of $60.40.

Kopp Family Office LLC decreased its holdings in shares of Vericel Corporation (NASDAQ:VCEL - Free Report) by 4.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 172,657 shares of the biotechnology company's stock after selling 8,554 shares during the quarter. Vericel comprises approximately 4.8% of Kopp Family Office LLC's holdings, making the stock its 7th biggest holding. Kopp Family Office LLC owned approximately 0.34% of Vericel worth $7,347,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in VCEL. Voloridge Investment Management LLC acquired a new position in shares of Vericel during the 4th quarter valued at $1,502,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Vericel by 17.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 112,837 shares of the biotechnology company's stock worth $6,196,000 after buying an additional 16,466 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Vericel in the 4th quarter worth $57,000. Mackenzie Financial Corp acquired a new position in Vericel in the 4th quarter worth $215,000. Finally, California State Teachers Retirement System lifted its holdings in Vericel by 4.6% in the 4th quarter. California State Teachers Retirement System now owns 45,857 shares of the biotechnology company's stock worth $2,518,000 after buying an additional 2,014 shares in the last quarter.

Vericel Price Performance

Vericel stock opened at $31.21 on Wednesday. The firm has a 50 day simple moving average of $35.54 and a 200-day simple moving average of $39.96. The stock has a market capitalization of $1.57 billion, a PE ratio of 260.11 and a beta of 1.33. Vericel Corporation has a 12-month low of $29.93 and a 12-month high of $63.00.

Vericel (NASDAQ:VCEL - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.03. The business had revenue of $63.24 million during the quarter, compared to analysts' expectations of $64.61 million. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The business's revenue was up 20.1% on a year-over-year basis. During the same period last year, the firm posted ($0.10) earnings per share. On average, analysts forecast that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on the stock. Stephens reiterated an "overweight" rating and issued a $67.00 price objective on shares of Vericel in a report on Monday, June 16th. BTIG Research lowered shares of Vericel from a "buy" rating to a "neutral" rating in a report on Wednesday, September 17th. Finally, Canaccord Genuity Group cut their price objective on shares of Vericel from $61.00 to $58.00 and set a "buy" rating on the stock in a report on Friday, August 1st. Four research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $60.40.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.